- Ingenuity Pathway Analysis Interpret extends analysis
capabilities of human-curated knowledge base with AI
technology
- AI-extension highlights key biological elements at work and
provides summarized results and interpretations in a sharable web
document, speeding up interpretation
- Ingenuity Pathway Analysis Interpret unlocks the full
potential of biological data by streamlining interpretation process
and delivering actionable insights for experiments
QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today
announced the launch of Ingenuity Pathway Analysis (IPA) Interpret,
a new feature designed to simplify and accelerate the
interpretation of complex biological data.
Leveraging AI technology, IPA Interpret helps distill complex
differential expression analyses into actionable insights, helping
researchers understand which genes are involved in a disease, a
biological process or a response to a drug or environmental
condition.
IPA, which forms the foundation of IPA Interpret, has over
50,000 citations and a high-quality, manually curated knowledge
base. This widely recognized platform structures and integrates
causal biomedical relationships between genes, diseases, functions,
targets, drugs chemicals, and other objects. With IPA's curated
knowledge base, scientists can confidently predict and validate
novel target-disease and drug-disease relationships.
By combining this extensive knowledge with advanced analyses and
AI algorithms, IPA Interpret now automatically analyzes, compares,
and contextualizes complex gene expression datasets available in
IPA, identifying key biological processes, pathways, and networks,
in a streamlined web-page report.
“IPA Interpret is a breakthrough in molecular data analysis,
combining the best of human expertise and AI technology,” said
Dominic John, Vice President, QIAGEN Digital Insights. “Our
augmented approach leveraging AI and Natural Language Processing
with humans ensures that our customers have trustworthy and quality
data with the causal relationships needed to drive AI insights. IPA
Interpret embodies this approach and empowers more researchers to
uncover deeper insights and make more informed decisions,
faster.”
One of the standout features of IPA Interpret is its ability to
generate comprehensive reports that can be easily shared with
colleagues and collaborators. With a simple link, researchers can
distribute their findings, fostering collaboration and accelerating
the dissemination of scientific knowledge. Additionally, IPA
Interpret provides updated graphical representations of key
results, enhancing the clarity and impact of the insights.
QIAGEN is continuously integrating AI technology in its QDI
portfolio. In early 2024, QIAGEN released an AI-driven biomedical
knowledgebase to drive data-driven drug discovery and in late 2023,
QIAGEN released an AI-driven enhancement to its market-leading
QIAGEN Clinical Insight Interpret product capabilities.
IPA Interpret is an integrated component of QIAGEN Ingenuity
Pathway Analysis and is available to active licensed subscribers.
For more information, please visit:
https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-ipa/qiagen-ipa-interpret/.
About QIAGEN Digital Insights
QIAGEN Digital Insights (QDI), the bioinformatics business of
QIAGEN, is the leading provider of genomic and clinical knowledge,
analysis and interpretation tools, and services for scientists and
clinicians. QDI has over 25 years of experience in the industry,
90,000 users worldwide, over 100,000 citations in scientific
papers, more than 3 million profiled patient cases, and over 40
billion scientific data points. The portfolio includes expertly
curated genomic and clinical knowledge solutions as well as
bioinformatics software and services for efficient data management,
sharing, and actionable insights. Learn more at
https://digitalinsights.qiagen.com/.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue, and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of September 30, 2024,
QIAGEN employed more than 5,900 people in over 35 locations
worldwide. Further information can be found at
https://www.qiagen.com/.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, timing for launch and development, marketing
and/or regulatory approvals, financial and operational outlook,
growth and expansion, collaborations, markets, strategy or
operating results, including without limitation its expected
adjusted net sales and adjusted diluted earnings results, are
forward-looking, such statements are based on current expectations
and assumptions that involve a number of uncertainties and risks.
Such uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses; actions of governments, global or regional economic
developments, weather or transportation delays, natural disasters,
political or public health crises, and its impact on the demand for
our products and other aspects of our business, or other force
majeure events; as well as the possibility that expected benefits
related to recent or pending acquisitions may not materialize as
expected; and the other factors discussed under the heading “Risk
Factors” in our most recent Annual Report on Form 20-F. For further
information, please refer to the discussions in reports that QIAGEN
has filed with, or furnished to, the U.S. Securities and Exchange
Commission.
Source: QIAGEN N.V.
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241212300959/en/
Investor Relations John Gilardi +49 2103 29
11711 Domenica Martorana +49 2103 29 11244 e-mail:
ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29
11826 Lisa Specht +49 2103 29 14181 e-mail:
pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Qiagen NV (NYSE:QGEN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
